Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirabegron Efficacy and Safety in Chinese OAB
NCT04562090Phase 4Completed
- Sponsor
- Astellas Pharma
- Start
- Jan 2021
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of mirabegron in overactive bladder (OAB), sponsored by Astellas Pharma. Primary endpoint: Change From Baseline to the End of 12-Week Treatment Period in Mean Number of Micturition/24 Hours in Mirabegron 50 mg Group. Started Jan 2021; status: completed.
02
Drugs
mirabegron
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT04562090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04562090.